HMC
TEVA icon

Harvard Management Company’s Teva Pharmaceuticals TEVA Stock Holding History

Harvard Management Company’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-44,712
Closed -$1.62M – 70
2016
Q4 		$1.62M Buy
+44,712
New +$1.79M 0.25% 43
2015
Q3 		– Sell
-38,000
Closed -$2.25M – 143
2015
Q2 		$2.25M Buy
+38,000
New +$2.34M 0.18% 78

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Harvard Management Company's TEVA Position: Q1 2017 in Review

Harvard Management Company sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 44,712 shares — an estimated $1.62M sold.

Harvard Management Company first reported a position in TEVA in Q2 2015 and held it in 2 quarters. The position peaked at $2.25M in Q2 2015. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Harvard Management Company reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Harvard Management Company sold 44,712 Teva Pharmaceuticals shares in Q1 2017, an estimated $1.62M.
  • Harvard Management Company first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Harvard Management Company's Teva Pharmaceuticals position peaked at $2.25M in Q2 2015.
  • 686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Harvard Management Company's 13F filing for Q1 2017, filed 12 May 2017.